BioLight announced that on January 10 2014, the company filed a registration statement on Form F-6 with the U.S. Securities and Exchange Commission (SEC) for the registration of American Depository Receipts (ADR) for trading in the OTC market (Level 1).
BioLight announced that its subsidiary, IOPtima (87.17%), has signed an exclusive distribution agreement with a leading distributor in the field of Ophthalmology in Taiwan in which the distributor will purchase at least 6 IOPtimate™ systems for performing a unique surgery to treat glaucoma.
BioLight hereby respectfully announces, that on October 10, 2013, the subsidiary Diagnostear Ltd, in which the company holds 70% of the issued and outstanding share capital (1), notified Diagnostear that it received approval for a grant from the Office of the Chief Scientist for a project concerning the development of …
BioLight announced today that its subsidiary, IOPtima (87.17%), has signed an exclusive distribution agreement with Tradis Gat, one of the leading importers and marketers of medical products in Israel, within the framework of which Tradis Gat has committed to purchase at least 8 IOPtimate™ systems for performing a unique surgery …
BioLight announced today that the Company’s Board of Directors approved the registration of ADR level 1, which will be traded in the over-the-counter market, subject to completion of the required procedures.
IOPtima Ltd. notified that the company that represents it in Mexico received a regulatory approval from the COFEPRIS (the regulatory authority that is subject to the Ministry of Health in Mexico), to sell and market the device which IOPtima developed (the IOPtiMateTM) in Mexico.
BioLight announced today that it is expanding its Glaucoma and Dry Eye Syndrome Cluster by means of investing, through a wholly owned subsidiary, in D.E.S. Diagnostics Ltd., which is developing an innovative stick that enables diagnosis and monitoring of Dry Eye Syndrome by examining various parameters in tear fluid.
Bio-Light announced that positive interim results have been obtained from a clinical trial conducted to assess the capability of Zetiq’s (wholly owned subsidiary of Micromedic) CellDetect® technology, to detect bladder cancer cells in urine specimens.
Bio-Light announced that the product CellDetect®, manufactured by Zetiq – a subsidiary under the full control of Micromedic, designed to diagnose cancerous cells in the cervix, has been approved by the State Food and Drug Administration (SFDA) of the People’s Republic of China for marketing in China.
BioLight Life Sciences Investments Ltd., a unique Biomedical firm engaged in the management and commercialization of Biomed innovation, announced today that it has successfully raised over $28 million through shares issue at the market price to the company’s shareholders and other public investors. Among the investors are Mr. Israel Makov, …